MLTX
Moonlake Immunotherapeutics Earnings
$46.06
Earnings Summary
Revenue | $0Mn |
Net Profits | $-35.39Mn |
Net Profit Margins | -Inf% |
Moonlake Immunotherapeutics’s revenue jumped NaN% since last year same period to $0Mn in the Q3 2024. On a quarterly growth basis, Moonlake Immunotherapeutics has generated NaN% jump in its revenue since last 3-months.
Moonlake Immunotherapeutics’s net profit fell -275.45% since last year same period to $-35.39Mn in the Q3 2024. On a quarterly growth basis, Moonlake Immunotherapeutics has generated -45.84% fall in its net profits since last 3-months.
Moonlake Immunotherapeutics’s net profit margin jumped NaN% since last year same period to -Inf% in the Q3 2024. On a quarterly growth basis, Moonlake Immunotherapeutics has generated NaN% jump in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Moonlake Immunotherapeutics post its latest quarter earningsEPS Estimate Current Quarter | -0.44 |
EPS Estimate Current Year | -0.44 |
Moonlake Immunotherapeutics’s earning per share (EPS) estimates for the current quarter stand at -0.44 - a -57.14% fall from last quarter’s estimates.
Moonlake Immunotherapeutics’s earning per share (EPS) estimates for the current year stand at -0.44.
Key Ratios
Key ratios of the Moonlake Immunotherapeutics post its Q3 2024 earningsEarning Per Share (EPS) | -0.56 |
Moonlake Immunotherapeutics’s earning per share (EPS) fell -211.11% since last year same period to -0.56 in the Q3 2024. This indicates that the Moonlake Immunotherapeutics has generated -211.11% annual rate of fall in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-08-07 | -0.28 | -0.39 | -39.29% |
2024-11-07 | -0.44 | -0.56 | -27.27% |
2024-05-07 | -0.19 | -0.22 | -15.79% |
₹0 US Stocks a/c Opening Fee